

1 **SUPPLEMENTAL MATERIAL**

2 Table S1. ROC curve analyses based on testing 816 sera for anti-HEV IgM and IgG.

3

---

	<b>Cut-off</b>	<b>Area under ROC curve +/- standard error</b>	<b>95% confidence interval</b>	<b>N reactive (N Single reactive)</b>	<b>N non-reactive (N False negative)</b>
<b>Anti-HEV IgM</b>					
Mikrogen	1.0	0.981 +/- 0.006	0.968- 0.994	35 <sup>1</sup> (13 <sup>2</sup> )	781 <sup>5</sup> (10)
DSI	1.0	0.9934 +/- 0.003	0.988- 0.999	46 <sup>1</sup> (13 <sup>2</sup> )	769 <sup>5</sup> (1 <sup>2</sup> )
Euro-immun	1.0	0.983 +/- 0.011	0.962 – 1.00	16 <sup>3</sup> (0)	800 <sup>7</sup> (18)
Axiom	1.0	0.9149 +/- 0.034	0.848-0.982	21 <sup>3</sup> (2)	795 <sup>7</sup> (16)
DiaPro	1.0	0.9641 +/- 0.018	0.930-0.998	49 <sup>1</sup> (18 <sup>2</sup> )	767 <sup>5</sup> (3)
<b>Anti-HEV IgG</b>					
Mikrogen	1.0	0.9639 +/- 0.008	0.949-0.979	138 <sup>4</sup> (4)	678 <sup>8</sup> (76 <sup>9</sup> )
DSI	1.0	0.9711 +/- 0.008	0.955-0.987	160 <sup>4</sup> (4)	656 <sup>8</sup> (55 <sup>9</sup> )

---

Euro-immune	0.8	0.9554+/- 0.009	0.938-0.973	95 <sup>5</sup> (4)	721 <sup>1</sup> (117 <sup>10</sup> )
Axiom	1.0	0.9887+/- 0.005	0.978-0.999	215 <sup>6</sup> (11)	601 <sup>11</sup> (7)
DiaPro	1.3	0.9969+/- 0.001	0.995-0.999	233 <sup>6</sup> (23)	583 <sup>11</sup> (1)

4

5 <sup>1</sup>11 HEV RNA positive sera; <sup>2</sup> one HEV RNA positive serum; <sup>3</sup>10 HEV RNA positive sera; <sup>4</sup>14 HEV RNA positive sera; <sup>5</sup>15 HEV RNA positive  
6 sera; <sup>6</sup>22 HEV RNA positive sera; <sup>7</sup>16 HEV RNA positive sera; <sup>8</sup>12 HEV RNA positive sera; <sup>9</sup>8 HEV RNA positive sera; <sup>10</sup>7 HEV RNA  
7 positive sera; <sup>11</sup>4 HEV RNA positive sera

8

9 Table S2. Results obtained from analyzing 500 serum samples from blood donors and 361 serum samples from patients for anti-HEV IgM with  
10 five assays.

11

	Blood donor samples	Patients with suspected hepatitis E	Patients with liver disease	Liver transplant recipients	TOTAL
	(No total positive; % total positive)	(No total positive; % total positive)	(No total positive; % total positive)	(No total positive; % total positive)	(No total positive; % total positive)
	(N= 500)	(N= 137)	(N= 156)	(N= 23)	(N= 816)

---

**Anti-HEV IgM**

Reactive in five assays	1 (0.2%)	13 <sup>1</sup> (9.5%)	0	0	14 <sup>1</sup> (2%)
Reactive in four assays only	0 (1; 0.2%)	1 <sup>2</sup> (14; 10%)	0	0	1 <sup>2</sup> (15; 1.8%)
Reactive in three assays only	1 (2; 0.4%)	6 (20; 15%)	1 (0.6%)	0	8 (23; 2.8%)
Reactive in two assays only	4 (6; 1.2%)	5 (25; 18%)	2 (3; 1.9%)	0	11 (34; 4.2%)
Reactive in one assay only	11 <sup>2</sup> (17; 3.4%)	26 <sup>3</sup> (51; 37%)	7 (10; 6.4%)	2 (8.7%)	46 <sup>4</sup> (80; 9.8%)
Non-reactive in five assays	483 <sup>5</sup> (97%)	86 <sup>5</sup> (63%)	146 <sup>4</sup> (94%)	21 <sup>3</sup> (91%)	736 <sup>6</sup> (90%)
Concordance in five assays	484 (97%)	98 (71%)	146 (94%)	21 (91%)	749 (87%)
Concordance in four assays	484 (97%)	100 (73%)	146 (94%)	21 (91%)	751 (87%)
Concordance in three assays	485 (97%)	106 (77%)	147 (94%)	21 (91%)	759 (88%)
Concordance in two assays	489 (98%)	111 (81%)	149 (96%)	21 (91%)	770 (89%)

---

12 <sup>1</sup>9 samples positive for HEV RNA; <sup>2</sup>one sample positive for HEV RNA; <sup>3</sup>two samples positive for HEV RNA; <sup>4</sup>3 samples positive for HEV RNA; <sup>5</sup>4 samples

13 positive for HEV RNA; <sup>6</sup>13 samples positive for HEV RNA

14 Table S3. Results obtained from analyzing 500 serum samples from blood donors and 361 serum samples from patients for anti-HEV IgG with  
15 five assays.

	Blood donor samples (No total positive; % total positive) (N= 500)	Patients with suspected hepatitis E (No total positive; % total positive) (N= 137)	Patients with liver disease (No total positive; % total positive) (N= 156)	Liver transplant recipients (No total positive; % total positive) (N= 23)	TOTAL (No total positive; % total positive) (N= 816)
<b>Anti-HEV IgG</b>					
Reactive in five assays	20 (4%)	52 <sup>1</sup> (38%)	9 <sup>2</sup> (5.8%)	4 <sup>2</sup> (17%)	85 <sup>3</sup> (10%)
Reactive in four assays only	13 <sup>2</sup> (33; 6.6%)	19 <sup>2</sup> (71; 52%)	12 (21; 13%)	0 (4; 17%)	44 <sup>4</sup> (129; 16%)
Reactive in three assays only	15 (48; 10%)	8 (79; 58%)	2 (23; 15%)	0 (4; 17%)	25 (154; 19%)
Reactive in two assays only	31 <sup>5</sup> (79; 16%)	12 <sup>4</sup> (91; 66%)	11 <sup>2</sup> (34; 22%)	2 (6; 26%)	56 <sup>6</sup> (210; 26%)
Reactive in one assay only	27 (106; 21%)	2 (93; 68%)	15 (49; 31%)	3 (9; 39%)	47 (257; 31%)
Non-reactive in five assays	394 (79%)	44 <sup>2</sup> (32%)	107 <sup>2</sup> (68%)	14 <sup>2</sup> (61%)	559 <sup>7</sup> (69%)
Concordance in five assays	414 (83%)	96 (70%)	116 (74%)	18 (78%)	644 (80%)
Concordance in four assays	427 (85%)	115 (84%)	128 (82%)	18 (78%)	688 (84%)
Concordance in three assays	442 (88%)	123 (90%)	130 (83%)	18 (78%)	713 (87%)
Concordance in two assays	473 (95%)	135 (99%)	141 (90%)	20 (87%)	769 (94%)

16 <sup>1</sup>12 samples positive for HEV RNA; <sup>2</sup>one sample positive for HEV RNA; <sup>3</sup>14 samples positive for HEV RNA; <sup>4</sup>2samples positive for HEV RNA; <sup>5</sup>4 samples positive  
17 for HEV RNA; <sup>6</sup>7 samples positive for HEV RNA; <sup>7</sup>3 samples positive for HEV RNA

Table S4. Results with indicated assay given as sample OD/cut-off OD from testing for anti-HEV IgM and IgG of consecutive sera according to time of sampling for 27 patients

Patient no	Period between samples	Mikrogen IgM/IgG	DSI IgM/IgG	Euro-immun IgM/IgG	Axiom IgM/IgG	DiaPro IgM/IgG	HEV
							RNA/genotype (gt)
1	-	<b>8.6/12.5</b>	<b>10.2/8.4</b>	<b>7.7/4.6</b>	<b>13.0/14.5</b>	<b>15.0/11.0</b>	+ /gt3
	4 months	<b>5.1/7.7</b>	<b>8.6/10.9</b>	<b>6.2/4.0</b>	<b>10.1/27.5</b>	<b>12.8/9.1</b>	+
	5 months	<b>3.7/8.2</b>	<b>8.4/11.1</b>	<b>5.6/4.2</b>	<b>8.6/26.7</b>	<b>12.3/9.0</b>	-
	7 months	<b>2.9/7.7</b>	<b>8.0/10.8</b>	<b>4.1/3.5</b>	<b>5.7/27.1</b>	<b>11.9/8.9</b>	-
2	-	<b>9.8/14.8</b>	<b>11.4/11.6</b>	<b>9.7/4.3</b>	<b>12.6/20.5</b>	<b>13.5/9.1</b>	+ /gt1
	3 weeks	<b>4.2/8.6</b>	<b>10.9/11.6</b>	<b>10.0/5.0</b>	<b>12.9/22.2</b>	<b>12.8/9.0</b>	+
6	-	<b>4.1/2.2</b>	<b>10.8/0.7</b>	<b>9.5/1.2</b>	<b>4.3/6.3</b>	<b>12.9/4.4</b>	+ /gt3
	1 week	<b>6.6/2.3</b>	<b>10.5/0.8</b>	<b>6.1/1.2</b>	<b>4.3/5.5</b>	<b>12.9/4.2</b>	+
9	-	<b>9.7/10.7</b>	<b>10.3/9.6</b>	<b>7.6/3.8</b>	<b>8.5/15.8</b>	<b>12.6/8.9</b>	+ /gt3
	2 weeks	<b>10.0/2.3</b>	<b>8.9/1.9</b>	<b>5.4/1.1</b>	<b>6.3/10.8</b>	<b>12.2/4.3</b>	+
10	-	0.4/0.2	0.0/0.0	0.0/0.1	0.0/0.0	0.2/0.4	-
	4 years	<b>2.7/12.2</b>	<b>2.8/11.3</b>	<b>1.2/4.6</b>	<b>1.9/28</b>	<b>9.4/8.8</b>	+ /gt3
13	-	<b>2.4/12.0</b>	<b>5.2/10.3</b>	<b>1.3/4.1</b>	<b>8.4/27.1</b>	<b>6.1/8.9</b>	+ /gt3
	2 months	<b>0.8/12.0</b>	<b>0.6/10.9</b>	<b>0.1/3.1</b>	<b>0.7/28.0</b>	<b>1.7/8.7</b>	+

---

21	-	<b>1.4/0.8</b>	<b>5.3/0.5</b>	0.4/0.3	0.2/ <b>14.6</b>	<b>2.3/5.5</b>	-
	3 weeks	<b>1.6/1.1</b>	<b>5.9/0.4</b>	0.4/0.3	0.2/ <b>13.0</b>	<b>2.5/4.9</b>	-
23	-	<b>1.1/1.5</b>	<b>2.5/5.0</b>	0.2/0.2	<b>3.7/28.0</b>	<b>2.1/6.8</b>	-
	5 months	0.4/ <b>1.1</b>	0.9/ <b>4.0</b>	0.3/0.4	<b>2.0/28.0</b>	0.5/ <b>6.0</b>	-
25	-	<b>1.1/1.1</b>	<b>2.3/1.6</b>	0.3/0.4	0.0/ <b>28.0</b>	<b>1.6/6.5</b>	-
	1 month	0.8/ <b>1.4</b>	<b>2.8/1.8</b>	0.2/0.5	0.0/ <b>27.8</b>	<b>1.8/7.2</b>	-
29	0	0.8/5.6	0.1/8.9	0.1/1.6	0.1/28.2	1.5/8.7	-
	2 years	0.8/6.6	0.2/9.3	0.1/1.9	0.0/28.0	1.4/9.1	-
30	-	0.6/ <b>2.7</b>	0.8/ <b>9.5</b>	0.2/ <b>1.0</b>	0.2/ <b>28.0</b>	<b>1.3/8.3</b>	-
	2 weeks	<b>1.1/3.8</b>	<b>1.1/10.3</b>	0.2/ <b>1.2</b>	0.1/ <b>28.0</b>	<b>1.5/8.5</b>	-
36	-	0.3/ <b>2.4</b>	0.3/ <b>11.0</b>	0.1/ <b>1.0</b>	0.0/ <b>28.0</b>	<b>1.1/8.6</b>	+
	1 week	0.2/ <b>3.2</b>	0.3/ <b>10.7</b>	0.1/ <b>1.0</b>	0.0/ <b>28.0</b>	0.9/ <b>9.1</b>	+
41	-	<b>2.4/1.4</b>	<b>1.2/2.4</b>	0.2/0.6	0.1/ <b>28.0</b>	<b>1.0/7.7</b>	-
	18 months	0.6/ <b>1.4</b>	<b>1.3/2.2</b>	0.3/0.5	0.1/ <b>28.0</b>	0.9/ <b>8.1</b>	-
47	-	0.1/ <b>2.0</b>	0.0/ <b>5.8</b>	0.0/ <b>1.5</b>	0.0/ <b>28.0</b>	0.8/ <b>8.8</b>	+
	2 months	0.2/ <b>2.7</b>	0.2/ <b>4.4</b>	0.0/ <b>1.7</b>	0.0/ <b>27.1</b>	0.7/ <b>8.5</b>	-

---

---

	6 months	<b>0.2/1.7</b>	<b>0.1/3.9</b>	<b>0.0/1.2</b>	<b>0.0/27.2</b>	<b>0.6/7.8</b>	-
	12 months	<b>0.1/1.5</b>	<b>0.0/3.6</b>	<b>0.0/1.1</b>	<b>0.0/27.2</b>	<b>0.4/7.5</b>	-
51	-	<b>0.3/5.2</b>	<b>0.4/8.5</b>	<b>0.1/1.3</b>	<b>0.0/28.0</b>	<b>0.7/8.3</b>	-
	5 years	<b>0.7/3.1</b>	<b>0.2/6.0</b>	<b>0.0/1.4</b>	<b>0.0/28.0</b>	<b>0.3/8.8</b>	-
57	-	<b>1.3/7.4</b>	<b>0.5/10.8</b>	<b>0.1/3.5</b>	<b>0.0/28.0</b>	<b>0.4/9.0</b>	-
	1 months	<b>0.7/5.8</b>	<b>1.7/8.3</b>	<b>0.1/2.4</b>	<b>0.0/28.0</b>	<b>0.5/8.9</b>	-
	3 months	<b>1.0/6.2</b>	<b>0.2/8.9</b>	<b>0.2/2.2</b>	<b>0.1/27.3</b>	<b>0.6/9.0</b>	-
75	-	<b>0.1/2.0</b>	<b>0.0/6.3</b>	<b>0.0/1.0</b>	<b>0.0/28.0</b>	<b>0.2/8.5</b>	-
	8 months	<b>0.2/2.4</b>	<b>0.0/8.6</b>	<b>0.1/1.0</b>	<b>0.0/27.7</b>	<b>0.4/8.3</b>	-
79	-	<b>0.2/1.6</b>	<b>0.0/6.6</b>	<b>0.0/0.7</b>	<b>0.1/28.0</b>	<b>0.4/8.7</b>	-
	13 months	<b>0.2/2.1</b>	<b>0.0/4.5</b>	<b>0.0/0.9</b>	<b>0.1/28.0</b>	<b>0.3/8.4</b>	-
84	-	<b>0.2/0.9</b>	<b>0.0/1.9</b>	<b>0.1/0.4</b>	<b>0.0/27.8</b>	<b>0.2/7.8</b>	-
	14 months	<b>0.2/2.9</b>	<b>0.0/3.8</b>	<b>0.0/0.6</b>	<b>0.0/27.7</b>	<b>0.3/8.7</b>	-
100	-	<b>0.2/2.4</b>	<b>0.7/7.2</b>	<b>0.1/1.1</b>	<b>0.0/28.0</b>	<b>0.3/8.8</b>	-
	19 months	<b>0.1/1.8</b>	<b>0.0/6.1</b>	<b>0.1/0.9</b>	<b>0.0/28.0</b>	<b>0.3/8.7</b>	-
	23 months	<b>0.2/3.0</b>	<b>0.2/8.6</b>	<b>0.0/1.4</b>	<b>0.0/28.0</b>	<b>0.2/8.7</b>	-
	28 months	<b>0.1/4.0</b>	<b>0.1/10.1</b>	<b>0.0/1.4</b>	<b>0.0/26.9</b>	<b>0.3/8.8</b>	-
104	-	<b>0.2/0.5</b>	<b>0.0/0.9</b>	<b>0.0/0.3</b>	<b>0.0/11.2</b>	<b>0.3/2.6</b>	+

---



---

	3 months	0.2/0.3	0.0/0.3	0.0/0.2	0.0/ <b>7.8</b>	0.2/ <b>1.7</b>	+
	6 months	0.3/0.6	0.0/0.3	0.0/0.2	0.0/ <b>6.3</b>	0.3/ <b>1.7</b>	-
111	-	0.4/0.2	<b>1.3</b> /0.0	0.0/0.1	0.0/0.1	0.3/0.9	-
	3 months	0.9/0.2	0.1/0.0	0.1/0.1	0.1/0.1	0.2/0.9	-
115	-	<b>2.1</b> /0.1	0.0/0.0	0.1/0.1	0.1/0.8	0.2/0.3	-
	2 weeks	<b>2.2</b> /0.1	0.0/0.0	0.0/0.1	0.2/0.4	0.3/0.3	-
117	-	0.1/ <b>1.8</b>	0.0/ <b>2.6</b>	0.0/0.6	0.0/ <b>27.5</b>	0.2/ <b>8.4</b>	-
	2 weeks	0.2/ <b>2.6</b>	0.0/ <b>2.3</b>	0.0/ <b>0.8</b>	0.0/ <b>27.4</b>	0.2/ <b>9.0</b>	-
132	-	0.3/ <b>1.3</b>	0.2/0.2	0.1/0.3	0.0/ <b>27.8</b>	0.2/ <b>8.8</b>	-
	3 weeks	0.3/0.8	0.2/0.9	0.1/0.4	0.0/ <b>28.0</b>	0.1/ <b>8.8</b>	-
134	-	0.5/ <b>4.4</b>	0.0/ <b>9.2</b>	0.0/ <b>1.2</b>	0.0/ <b>28.0</b>	0.2/ <b>8.6</b>	+
	1 month	<b>1.1</b> / <b>4.8</b>	0.0/ <b>9.1</b>	0.0/ <b>1.9</b>	0.0/ <b>28.0</b>	0.2/ <b>8.5</b>	-
180	-	0.1/ <b>1.0</b>	0.0/ <b>3.0</b>	0.0/0.5	0.0/ <b>27.8</b>	0.2/ <b>6.9</b>	-
	1 year	0.1/ <b>1.2</b>	0.0/ <b>2.2</b>	0.0/0.4	0.0/ <b>27.5</b>	0.1/ <b>6.7</b>	-





---


### **Supplemental figure legends**

Figure S1 a-j. Log[OD values/cutoff values] for each of the 861 sera with two assays being compared in each graph. Sera represented in the lower left quadrant are negative in both assays, those in the upper right quadrant are positive with both assays. Sera represented in the lower right quadrant are positive with the assay indicated on the X-axis, and negative in the assay on the Y-axis. Those in the upper left quadrant are negative with the assay indicated on the X-axis, and positive with the assay indicated on the Y-axis.


Figure S2. Regression analysis of log[OD values of dilutions/cut-off value of the assay] in relation to log[dilution] for determination of end-point titers for anti-HEV IgM in WHO reference reagent NIBSC code: 94/584 with the indicated assay.

Figure S3. Age distribution of blood donors and patients analysed for anti-HEV IgM, IgG and HEV RNA.







- ◆ Blood donors
- ▲ Liver disease patients
- Suspected hepatitis E
- Liver transplant patients



- ◆ Blood donors
- ▲ Liver disease patients
- Suspected hepatitis E
- Liver transplant patients



- ◆ Blood donors
- ▲ Liver disease patients
- Suspected hepatitis E
- Liver transplant patients



- ◆ Blood donors
- ▲ Liver disease patients
- Suspected hepatitis E
- Liver transplant patients




Figure S1 a-j.  $\text{Log}[\text{OD values/cutoff values}]$  for each of the 861 sera with two assays being compared in each graph. Sera represented in the lower left quadrant are negative in both assays, those in the upper right quadrant are positive with both assays. Sera represented in the lower right quadrant are positive with the assay indicated on the X-axis, and negative in the assay on the Y-axis. Those in the upper left quadrant are negative with the assay indicated on the X-axis, and positive with the assay indicated on the Y-axis.








Figure S2. Regression analysis of log[OD values of dilutions/cut-off value of the assay] in relation to log[dilution] for determination of end-point titers for anti-HEV IgM in WHO reference reagent NIBSC code: 94/584 with the indicated assay.




Figure S3. Age distribution of blood donors and patients analysed for anti-HEV IgM, IgG and HEV RNA.